reports
Caredx Inc: 2 directors
A director at Caredx Inc sold 20,000 shares at 24.657USD and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
CareDx Receives CE Mark for AlloSeq HCT for Use in Hematopoietic Cell ...
CareDx Receives CE Mark for AlloSeq HCT for Use in Hematopoietic Cell Transplantation CareDx Expands Transplant Portfolio in Europe SOUTH SAN FRANCISCO, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it has received CE marking for its AlloSeq HCT chimerism testing kit and AlloSeq HCT interpretation software for use in patients who have received hematopoieti...
CareDx Sponsored ISHLT Innovation Challenge Award Tackles Chronic Lung...
CareDx Sponsored ISHLT Innovation Challenge Award Tackles Chronic Lung Allograft Dysfunction Donor-Derived Cell-Free DNA will be Used to Evaluate Treatment to Improve Lung Transplant Outcomes SOUTH SAN FRANCISCO, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the International Society for Heart and Lung Transplantation (ISHLT) has selected Dr. Berta Sáez-Gim...
In CareDx-Initiated IP Litigation Against Natera, Natera Now Drops 1 o...
In CareDx-Initiated IP Litigation Against Natera, Natera Now Drops 1 of 2 Patents Originally Asserted Against CareDx Natera Recycles Old IP for New Lawsuits SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that Natera has just dropped one of their two patents originally asserted against CareDx. At the same time, Natera asserted two patents tha...
CareDx Showcases Latest Innovation in Transplantation at European EFI ...
CareDx Showcases Latest Innovation in Transplantation at European EFI 2022 Conference Posters and Symposium Feature Latest Advances in AlloSeq Portfolio Including HLA Typing and Hematopoietic Stem Cell and Organ Transplant Monitoring SOUTH SAN FRANCISCO, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will be presenting the latest information on its AlloSeq® po...
CareDx Reports First Quarter 2022 Results
CareDx Reports First Quarter 2022 Results SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today reported financial results for the first quarter ended March 31, 2022. Recent Highlights: Achieved total revenue of $79.4 million for the three months ended March 31, 2022, increasing 18% year-over-yearProvided approximately 42,600 AlloSure and AlloMap patient resu...
CareDx Validates Clinical Performance of AlloMap Kidney to Comprehensi...
CareDx Validates Clinical Performance of AlloMap Kidney to Comprehensively Assess Transplant Rejection OKRA Multi-Center Prospective Study Confirms AlloMap Kidney Detects ABMR and TCMR Allograft Rejection SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – today announced the publication1 of new data demonstrating that AlloMap® Kidney gene-expression profiling predicts the prob...
CareDx Congratulates Board Member Dr. Hannah Valantine on ISHLT Lifeti...
CareDx Congratulates Board Member Dr. Hannah Valantine on ISHLT Lifetime Achievement Award SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that Board member Hannah Valantine MD, a recognized leader in driving heart transplantation innovations and health equity, has received the 2022 Lifetime Achievement Award from the International Society for...
CareDx Extends Artificial Intelligence Leadership to Heart Transplanta...
CareDx Extends Artificial Intelligence Leadership to Heart Transplantation New Addition to CareDx HeartCare Multimodality Portfolio Can Enable More Precise, Personalized Patient Care SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that through its ongoing partnership with OrganX, a non-profit health organization focused on cutting-edge digita...
CareDx to Report First Quarter 2022 Financial Results
CareDx to Report First Quarter 2022 Financial Results SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – today announced it will report financial results for the first quarter 2022 after market close on Thursday, May 5, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in l...
International Society for Heart and Lung Transplantation Foundation Se...
International Society for Heart and Lung Transplantation Foundation Selects Reg Seeto as Corporate Chair CareDx CEO and President, Reg Seeto, Joins ISHLT Foundation Global Steering Committee Focused on Driving Innovations for Heart and Lung Transplant Patients SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced Reg Seeto’s selection by the newly...
CareDx Demonstrates Potential of AlloHeme and AlloCell for Allogeneic ...
CareDx Demonstrates Potential of AlloHeme and AlloCell for Allogeneic Cell Transplant and Therapy Monitoring at Transplantation & Cellular Therapy Meetings CareDx Announces that OTTR Patient Management Software Now Validated for SMART on FHIR SOUTH SAN FRANCISCO, Calif., April 22, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the presentation of new data during the Tandem Meeti...
CareDx Supports UC Davis Health Pluralist Program Aimed at Reducing He...
CareDx Supports UC Davis Health Pluralist Program Aimed at Reducing Health Disparities in Organ Transplantation SOUTH SAN FRANCISCO, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that as part of its investment in health equity improvements, it is contributing to a new program led by UC Davis Health that aims to improve knowledge about and access to organ donatio...
CareDx Showcases Leadership with Over 25 Oral Presentations and Poster...
CareDx Showcases Leadership with Over 25 Oral Presentations and Posters at the International Society for Heart and Lung Transplantation Meeting Data Highlights Clinical Utility of CareDx Solutions, Including Findings from Surveillance HeartCare Outcomes Registry (SHORE) Demonstrating Power of Multimodality Assessment for More Precise Interventions CareDx Symposia Feature Latest Advancements Including XenoSure and XenoMap SOUTH SAN FRANCISCO, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commerc...
CareDx Reports Over 200,000 Heart Transplant Patient Results Served
CareDx Reports Over 200,000 Heart Transplant Patient Results Served CareDx Testing Services Have Been Used in Over 30,000 Heart Transplant Patients and Over 90 Percent of Centers in the United States SOUTH SAN FRANCISCO, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it has delivered over 200,000 AlloMap® or AlloSure® results for over 30,000 heart transpla...
CareDx, the Leading Sponsor of UNOS Transplant Management Forum, Demon...
CareDx, the Leading Sponsor of UNOS Transplant Management Forum, Demonstrates the Value of Digital Solutions to Improve Pre-Transplant Patient Referral and Waitlisting Workflow CareDx’s TxAccess Digital Platform Helps Move Pre-Transplant Patients to Transplant Faster SOUTH SAN FRANCISCO, Calif., April 11, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will host a lunch and l...
CareDx to Host Symposium at CEoT Featuring the Latest Multimodality In...
CareDx to Host Symposium at CEoT Featuring the Latest Multimodality Innovations in Kidney and Lung Transplant Surveillance Symposium, “Improved Precision with a Multimodality Approach,” Reviews Innovative Solutions for a More Holistic View of Allograft Health SOUTH SAN FRANCISCO, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will host the symposium, “Improv...
CareDx Partners with the European Society for Organ Transplantation to...
CareDx Partners with the European Society for Organ Transplantation to Provide Clinical Evidence Supporting the Use of AlloSeq cfDNA with European Transplant Healthcare Professionals SOUTH SAN FRANCISCO, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it is partnering with the European Society for Organ Transplantation (ESOT) to provide education for its memb...
CareDx Partners with HeartBrothers Foundation to Help Patients Living ...
CareDx Partners with HeartBrothers Foundation to Help Patients Living with Heart Failure and Heart Transplant SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it is partnering with the HeartBrothers Foundation as a corporate member and also hosting a patient education webinar together. HeartBrothers is a non-profit organization dedicated t...
CareDx’s AlloCare App Now Integrated with TxAccess to Help Pre-Transpl...
CareDx’s AlloCare App Now Integrated with TxAccess to Help Pre-Transplant Patients Navigate the Waitlist Process New Features Aim to Help More Patients with Kidney Failure Receive an Organ Transplant SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that its popular, user-friendly AlloCare® mobile phone health app, now features a “virtual road...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.